Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-09-30 Interim / Quarterly Rep…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
HY 2024 report Sequana Medical_NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Verkorte Geconsolideerde Jaarrekening' (Condensed Consolidated Financial Statements) for the first semester of 2024. It contains comprehensive financial statements, including the balance sheet, income statement, cash flow statement, and detailed notes, which are characteristic of an interim or quarterly report. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year (H1 2024). H1 2024
2024-09-30 Dutch
240808 PR Transparency Notif _ Newton Biocapital_ENG_FINAL.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparency Notification from Shareholders" and explicitly states that the company received a notification regarding the number of voting rights held by a shareholder (Newton Biocapital I SA), detailing a passive crossing of a threshold (2.74%). This type of disclosure, concerning changes in major shareholdings and voting rights, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the notification of a change in significant ownership.
2024-08-09 English
240808 PR Transparency Notif _ Newton Biocapital_NL_FINAL.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantiekennisgeving van Aandeelhouders" (Shareholder Transparency Notification) and details a notification received by Sequana Medical NV regarding a change in the shareholding percentage of Newton Biocapital I SA, specifically noting a passive crossing/undercrossing of the 3% threshold. This type of filing, which reports changes in significant share ownership levels by individuals or entities, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is presented as a press release, the core content is the mandatory disclosure of a change in major shareholding.
2024-08-09 Dutch
Sequana Medical - Transparency notification PR (ENG) - 5 August 2024.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Transparency Notification from Shareholders' and explicitly details the receipt of a notification regarding a change in major shareholding (GRAC société simple crossing below the 5% threshold). It cites the relevant Belgian Act on the disclosure of major participations. This content directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. Although it is presented as a press release ('PRESS RELEASE REGULATED INFORMATION'), the core subject matter is the shareholder notification itself, making MRQ the most specific classification over the general RNS.
2024-08-05 English
Sequana Medical - Transparency notification PR (NL) - 5 August 2024.pdf
Major Shareholding Notification Classification · 99% confidence The document is titled "Transparantiekennisgeving van Aandeelhouders" (Transparency Notification of Shareholders) and details a notification received by Sequana Medical regarding a change in shareholding percentage by GRAC société simple, which resulted in crossing a threshold (falling below 5%). It explicitly references Belgian transparency laws and the requirement for disclosure when voting rights thresholds (3%, 5%, 10%, etc.) are reached or crossed. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory announcement, MRQ is more specific than the general RNS category.
2024-08-05 Dutch
Sequana Medical - Transparency notification PR (ENG) - 1 August 2024.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Transparency Notification from Shareholders' and explicitly states that the company 'announces today that it received a transparency notification' regarding voting rights held by specific parties. It details the percentage of total outstanding shares held by these parties (22.53%) and references the relevant Belgian Act for disclosure of major participations. This content directly corresponds to notifications about changes in significant share ownership crossing regulatory thresholds. Therefore, the appropriate classification is Major Shareholding Notification (MRQ).
2024-08-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.